Alvotech
Business
Alvotech develops and manufactures biosimilar medicines, operating as a vertically integrated biotech company focused exclusively on biosimilars. Its main products and services include developed and manufactured biosimilar therapeutics (two approved products and multiple candidates such as AVT02, AVT04, AVT03, AVT06) together with regulatory dossiers, supply agreements and licensing of intellectual property to commercialization partners. Key business capabilities comprise an end-to-end platform spanning cell line and process development, analytical characterization, GMP manufacturing, clinical development and regulatory strategy. Alvotech distributes its products globally through strategic regional commercial partners covering the United States, Europe, Japan, Canada, Asia, the Middle East, Latin America and other international markets.
Summary from filing dated 2025-03-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $27.90M |
| Total assets | $1.49B |
| Total liabilities | $1.77B |
| Stockholders' equity | — |
| Operating cash flow | — |